GSK's 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US
Thursday, 26 March 2015
GSK is encouraging academic scientists in Europe, Canada and the US to submit their novel early drug discovery research proposals into its third annual Discovery Fast Track Challenge - a programme designed to accelerate the translation of early-stage research into game-changing new medicines.
AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
Wednesday, 25 March 2015
AstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca's compound library in the search for new treatments for diabetes.
Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research program focused on autoimmune diseases
Tuesday, 24 March 2015
Bristol-Myers Squibb Company (NYSE:BMY) today announced the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
Pfizer and Lilly preparing to resume Phase 3 chronic pain program for Tanezumab
Monday, 23 March 2015
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Medical expansion has led people worldwide to feel less healthy
Friday, 20 March 2015
Across much of the Western world, 25 years of expansion of the medical system has actually led to people feeling less healthy over time, a new study has found. A researcher at The Ohio State University used several large multinational datasets to examine changes in how people rated their health between 1981 and 2007 and compared that to medical expansion in 28 countries that are members of the Organization for Economic Co-operation and Development.
Study raises concerns about reporting of noninferiority trials
Thursday, 19 March 2015
An examination of the reporting of noninferiority clinical trials raises questions about the adequacy of their registration and results reporting within publicly accessible trial registries, according to a study in the March 17 issue of JAMA. Noninferiority clinical trials are designed to determine whether an intervention is not inferior to a comparator by more than a prespecified difference (known as the noninferiority margin).
AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD
Wednesday, 18 March 2015
AstraZeneca today announced positive top-line results from the Phase III PINNACLE programme, which included two pivotal 24-week studies (PINNACLE 1 and PINNACLE 2) to investigate the potential of PT003 to improve lung function in patients with Chronic Obstructive Pulmonary Disease (COPD).